Adrihal 10mg Injection

About

Adrihal 10mg Injection is a powerful antineoplastic agent used in the management of various cancers. Its mechanism of action involves disrupting the integrity and function of DNA within rapidly dividing cancer cells. This is primarily achieved through DNA intercalation and inhibition of topoisomerase II, enzymes essential for DNA replication and repair. These actions lead to DNA strand breaks and ultimately trigger programmed cell death (apoptosis), thereby inhibiting tumor growth and proliferation. Administered intravenously, Adrihal ensures systemic distribution, making it an effective treatment option for both localized and metastatic disease. It is often utilized as part of a multi-drug chemotherapy regimen to enhance overall therapeutic efficacy and improve patient outcomes.

Uses

• Treatment of various solid tumors.
• Management of certain leukemias and lymphomas.
• Adjuvant therapy in specific cancer types.
• Palliative treatment for advanced cancers.

Directions For Use

Adrihal 10mg Injection is administered intravenously by a qualified healthcare professional. The precise dosage, infusion rate, and treatment schedule will be determined by your doctor based on your specific medical condition and response to treatment.

Benefits

• Effective in inhibiting cancer cell proliferation.
• Contributes to significant tumor reduction.
• Can prolong progression-free survival.
• A key component in many successful chemotherapy protocols.
• Offers a systemic approach to managing widespread cancer.
• May improve overall patient prognosis.

Side Effects

• Nausea and vomiting
• Fatigue
• Hair loss (alopecia)
• Myelosuppression
• Mucositis
• Diarrhea
• Cardiotoxicity
• Red urine discoloration
• Injection site reactions
• Anorexia
• Increased risk of infection
• Peripheral neuropathy

Safety Measures

• Alcohol - Avoid alcohol consumption as it may exacerbate liver toxicity, increase gastrointestinal side effects, and impair overall health during treatment.
• Pregnancy - Adrihal is contraindicated during pregnancy due to its potential for severe fetal harm and teratogenicity. Effective contraception is required for both male and female patients during and after treatment.
• Breastfeeding - Breastfeeding is not recommended during Adrihal treatment as the drug may be excreted into breast milk and could cause serious adverse effects in the nursing infant.
• Liver - Use with caution in patients with hepatic impairment; dose adjustments may be necessary, and regular liver function monitoring is crucial due to potential hepatotoxicity.
• Kidney - Caution is advised in patients with renal impairment; dose modifications may be required based on kidney function to prevent drug accumulation and increased toxicity.
• Lung - Monitor for signs of pulmonary toxicity, such as cough or shortness of breath, as some antineoplastic agents can cause interstitial lung disease or pneumonitis.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.